CLINICAL TRIALS PROFILE FOR DOCEFREZ

All Clinical Trials for DOCEFREZ

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00075374 ↗	Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2003-10-01	RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which docetaxel regimen is more effective for non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of docetaxel in treating patients who have not previously received chemotherapy for unresectable stage IIIB or stage IV non-small cell lung cancer.
NCT00075374 ↗	Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer	Completed	Case Comprehensive Cancer Center	Phase 2	2003-10-01	RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which docetaxel regimen is more effective for non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of docetaxel in treating patients who have not previously received chemotherapy for unresectable stage IIIB or stage IV non-small cell lung cancer.
NCT00260611 ↗	Study of Oxaliplatin and Taxotere in Prostate Cancer	Completed	Sanofi	Phase 2	2004-11-01	The primary objective for this study is to evaluate PSA response rates (response will be defined as a > 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity (tolerance/safety).
NCT00260611 ↗	Study of Oxaliplatin and Taxotere in Prostate Cancer	Completed	University of Pittsburgh	Phase 2	2004-11-01	The primary objective for this study is to evaluate PSA response rates (response will be defined as a > 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity (tolerance/safety).
NCT00911820 ↗	Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer	Active, not recruiting	Genentech, Inc.	Phase 2	2009-07-01	There is no clear standard of care for metastatic stomach or esophageal cancer in the United States. The purpose of this research study is to determine the differences between two regimens of chemotherapy; Arm A: PCA (Cisplatin, Irinotecan and Bevacizumab) and Arm B: TPCA (Docetaxel, Cisplatin, Irinotecan and Bevacizumab). Docetaxel, Cisplatin, and Irinotecan are traditional chemotherapy drugs. Bevacizumab is an antibody (a protein that attacks a foreign substance in the body). Bevacizumab is believed to stop the formation of new blood vessels that carry nutrients to tumors. Both of the chemotherapy regimens (PCA and TPCA) have been studied in patients with esophageal and gastric cancer, and we are trying to determine if one regimen will keep your cancer from growing and improve how long you can live.
NCT00911820 ↗	Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer	Active, not recruiting	Massachusetts General Hospital	Phase 2	2009-07-01	There is no clear standard of care for metastatic stomach or esophageal cancer in the United States. The purpose of this research study is to determine the differences between two regimens of chemotherapy; Arm A: PCA (Cisplatin, Irinotecan and Bevacizumab) and Arm B: TPCA (Docetaxel, Cisplatin, Irinotecan and Bevacizumab). Docetaxel, Cisplatin, and Irinotecan are traditional chemotherapy drugs. Bevacizumab is an antibody (a protein that attacks a foreign substance in the body). Bevacizumab is believed to stop the formation of new blood vessels that carry nutrients to tumors. Both of the chemotherapy regimens (PCA and TPCA) have been studied in patients with esophageal and gastric cancer, and we are trying to determine if one regimen will keep your cancer from growing and improve how long you can live.

Clinical Trial Conditions for DOCEFREZ

Condition Name

Condition Name for DOCEFREZ
Intervention	Trials
Prostate Cancer	4
Urothelial Carcinoma	2
Gastric Cancer	2
Non Small Cell Lung Cancer	2

Condition MeSH

Condition MeSH for DOCEFREZ
Intervention	Trials
Prostatic Neoplasms	5
Carcinoma, Non-Small-Cell Lung	4
Carcinoma	4
Squamous Cell Carcinoma of Head and Neck	3

Clinical Trial Locations for DOCEFREZ

Trials by Country

Trials by Country for DOCEFREZ
Location	Trials
United States	50
France	4
Taiwan	3
United Kingdom	2
Spain	2

Trials by US State

Trials by US State for DOCEFREZ
Location	Trials
Texas	7
Florida	4
California	4
Massachusetts	4
Pennsylvania	4

Clinical Trial Progress for DOCEFREZ

Clinical Trial Phase

Clinical Trial Phase for DOCEFREZ
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	9
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for DOCEFREZ
Clinical Trial Phase	Trials
Recruiting	3
Terminated	3
Withdrawn	3

Clinical Trial Sponsors for DOCEFREZ

Sponsor Name

Sponsor Name for DOCEFREZ
Sponsor	Trials
Dana-Farber Cancer Institute	3
The University of Texas Health Science Center, Houston	2
University of Pittsburgh	1

Sponsor Type

Sponsor Type for DOCEFREZ
Sponsor	Trials
Industry	12
Other	11
NIH	1

Docefrez Clinical Trials Update and Market Outlook

Last updated: April 28, 2026

What is Docefrez’s current clinical development status?

No public, citable sources were available in the provided materials to identify Docefrez (drug INN/brand), its active ingredient, indication(s), or its trial registry footprint (e.g., ClinicalTrials.gov / EU CTR / WHO ICTRP). Without verifiable identifiers, a complete, accurate clinical trials update cannot be produced.

What do the latest trial results imply for dose, efficacy, and safety?

No citable trial publications, registry entries, or congress abstracts were available to evaluate:

• endpoints used (PFS/OS/ORR, ACR response, PASI, HbA1c, etc.)
• regimen specifics (dose, schedule, combination partners)
• safety findings (TEAEs, Grade 3/4 AEs, discontinuation rates)
• subgroup outcomes

Where does Docefrez sit in the competitive landscape?

No indication and mechanism were available to benchmark Docefrez against:

• direct competitors in the same MOA class
• label-to-label incumbents in the same patient segment
• active development players with overlapping endpoints and inclusion criteria

What is the addressable market for Docefrez?

No indication and geography scope were available to quantify:

• epidemiology or diagnosed prevalence base
• eligible population definitions
• penetration rates under label and formulary constraints
• pricing assumptions and payer coverage pathways

What is the revenue and adoption projection for Docefrez?

No definable inputs were available to build a credible revenue model, including:

• launch year, route, and label size
• trial-to-market translation metrics (response rates, duration of effect)
• competitive dynamics (pricing pressure, switching costs, standard-of-care adoption)
• reimbursement timelines and channel mix

What will determine commercial success or failure for Docefrez?

Without an identified product profile (indication, MOA, and trial outcomes), the decision drivers cannot be mapped to verifiable facts such as:

• probability of technical and regulatory success by endpoint category
• differentiation strategy vs. standard-of-care
• health-technology-assessment posture (ICER, budget impact, avoided utilization)
• lifecycle plan (next-gen formulations, combination expansions)

---

Key Takeaways

• A complete clinical trials update and market projection for Docefrez cannot be produced from the available information because the drug’s identifying details (active ingredient, indication, and registry trail) are not verifiable.
• No citable evidence was available to support trial status, results, competitive benchmarking, addressable market sizing, or revenue modeling.

---

FAQs

1. What is Docefrez’s active ingredient and indication?
   Not provided in the available materials in a form that can be verified.

2. Which phase is Docefrez in right now?
   Not verifiable without a trial registry or publication record.

3. Are there any published efficacy or safety results for Docefrez?
   None were available in the provided materials.

4. Who are Docefrez’s main competitors?
   Competitors cannot be identified without the indication and mechanism of action.

5. When could Docefrez be approved and launched?
   Launch timing cannot be projected without a documented regulatory and clinical development pathway.

---

References

No sources were available to cite.